145 related articles for article (PubMed ID: 38243710)
1. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.
Kwon OC; Lee HS; Yang J; Park MC
Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38243710
[TBL] [Abstract][Full Text] [Related]
2. Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study.
Ahn SM; Kim M; Kim YJ; Lee Y; Kim YG
J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160082
[TBL] [Abstract][Full Text] [Related]
3. TNF-alpha inhibitors for ankylosing spondylitis.
Maxwell LJ; Zochling J; Boonen A; Singh JA; Veras MM; Tanjong Ghogomu E; Benkhalti Jandu M; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2015 Apr; (4):CD005468. PubMed ID: 25887212
[TBL] [Abstract][Full Text] [Related]
4. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
[TBL] [Abstract][Full Text] [Related]
5. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
[TBL] [Abstract][Full Text] [Related]
6. The Risk of Major Adverse Cardiovascular Events in Ankylosing Spondylitis Patients With a History of Acute Anterior Uveitis: A Nationwide, Population Based Cohort Study.
Bai YC; Liu CH; Leong PY; Lai KL; Chen HH; Wei JC
Front Med (Lausanne); 2022; 9():884800. PubMed ID: 35872802
[TBL] [Abstract][Full Text] [Related]
7. Incident and recurrent herpes zoster for first-line bDMARD and tsDMARD users in seropositive rheumatoid arthritis patients: a nationwide cohort study.
Jeong S; Choi S; Park SM; Kim J; Ghang B; Lee EY
Arthritis Res Ther; 2022 Jul; 24(1):180. PubMed ID: 35902964
[TBL] [Abstract][Full Text] [Related]
8. Anterior uveitis in patients with spondyloarthritis treated with secukinumab or tumour necrosis factor inhibitors in routine care: does the choice of biological therapy matter?
Lindström U; Bengtsson K; Olofsson T; Di Giuseppe D; Glintborg B; Forsblad-d'Elia H; Jacobsson LTH; Askling J
Ann Rheum Dis; 2021 Nov; 80(11):1445-1452. PubMed ID: 34130984
[TBL] [Abstract][Full Text] [Related]
9. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
[TBL] [Abstract][Full Text] [Related]
10. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
11. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
[TBL] [Abstract][Full Text] [Related]
12. Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.
Escudero-Vilaplana V; Ramírez-Herráiz E; Alañón-Plaza E; Trovato-López N; García-Vicuña R; Carreño-Pérez L; Morell-Baladrón A; Sanjurjo-Sáez M
Int J Clin Pharm; 2015 Oct; 37(5):808-14. PubMed ID: 25910480
[TBL] [Abstract][Full Text] [Related]
13. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
14. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
van Bentum RE; Heslinga SC; Nurmohamed MT; Gerards AH; Griep EN; Koehorst CBJM; Kok MR; Schilder AM; Verhoef M; van der Horst-Bruinsma IE
J Rheumatol; 2019 Feb; 46(2):153-159. PubMed ID: 30385705
[TBL] [Abstract][Full Text] [Related]
15. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of secukinumab in ankylosing spondylitis from the Canadian perspective.
Goeree R; Chiva-Razavi S; Gunda P; Jain M; Jugl SM
J Med Econ; 2019 Jan; 22(1):45-52. PubMed ID: 30346844
[TBL] [Abstract][Full Text] [Related]
17. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
Kim Y; Park S; Kim HS
Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
[TBL] [Abstract][Full Text] [Related]
18. Disproportional signal of pericarditis with biological diseasemodifying antirheumatic drugs (bDMARDs) in patients with ankylosing spondylitis: a disproportionality analysis in the FAERS database.
Xia S; Li YF; Raschi E; Zhang BK; Noguchi Y; Sarangdhar M; Yan M; Ma JA
Front Pharmacol; 2024; 15():1275814. PubMed ID: 38333008
[No Abstract] [Full Text] [Related]
19. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
Silvagni E; Bortoluzzi A; Carrara G; Zanetti A; Govoni M; Scirè CA
BMJ Open; 2018 Sep; 8(9):e021447. PubMed ID: 30206082
[TBL] [Abstract][Full Text] [Related]
20. Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients.
Choi EY; Lee M; Lee CS
Clin Exp Rheumatol; 2020; 38(6):1132-1137. PubMed ID: 32828140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]